Zobrazeno 31 - 40
of 93
pro vyhledávání: '"Hwa-ping Feng"'
Autor:
Xu Min Zhao, Bernard M.Y. Cheung, M.Y.F. Yuen, Wendy W. Yeh, Shengmei Mu, Hwa-Ping Feng, Jiangdian Wang, Tommy Tsang Cheung, Zaiqi Wang, Joanne Wing Yan Chiu, Wenting Li, Karen S.L. Lam
Publikováno v:
Clinical therapeutics. 40(5)
Purpose This study evaluated the single- and multiple-dose pharmacokinetic (PK) variables of elbasvir and grazoprevir in healthy Chinese individuals. Methods This study was a 2-part, parallel-arm, open-label trial. In part 1, single-dose PK variables
Autor:
Edward O'Mara, Joan R. Butterton, Wen H. Lin, John A. Wagner, Hwa-Ping Feng, Lynn Webster, R. Douglas Bruce, Ellen G. J. Hulskotte, Feng Xuan
Publikováno v:
European Journal of Clinical Pharmacology. 71:303-311
Intravenous opioid use is a common route of hepatitis C virus (HCV) infection; consequently, the prevalence of HCV is high among patients on methadone or buprenorphine/naloxone. The authors evaluated the pharmacokinetic interaction of boceprevir with
Autor:
Luzelena Caro, Dennis Wolford, Zifang Guo, Christine Fandozzi, Jennifer Talaty, Marian Iwamoto, Wendy W. Yeh, Deborah Panebianco, Hwa-Ping Feng, Joan R. Butterton
Publikováno v:
Journal of clinical pharmacology. 58(5)
Elbasvir (EBR)/grazoprevir (GZR) may be coadministered with immunosuppressant drugs in posttransplant people who are infected with hepatitis C virus. The aim of the present study was to assess the safety and pharmacokinetic interactions between EBR a
Autor:
Joan R. Butterton, Terry E. O’Reilly, Craig R. Shadle, Hwa-Ping Feng, Wen H. Lin, John A. Wagner
Publikováno v:
European Journal of Clinical Pharmacology. 70:1107-1113
The purpose of this study was to examine drug interactions between boceprevir, a hepatitis C virus NS3/4A protease inhibitor, and a combined oral contraceptive containing ethinyl estradiol (EE) and norethindrone (NE). A single-center, open-label stud
Autor:
Daisuke Takahari, Kazuo Noguchi, Takayuki Yoshino, Takashi Shimamoto, Nozomu Fuse, Kei Muro, Atsushi Ohtsu, Hwa-ping Feng, Toshihiko Doi, Takashi Ura
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The safety, tolerability, and pharmacokinetic (PK) interactions of MK-0646 in combination with cetuximab and irinotecan were investigated in Japanese patients with advanced colorectal cancer. Methods Twenty patients were treated in the follow
Autor:
Ellen G. J. Hulskotte, M. G. J. A. van Zutven, Edward O'Mara, Joan R. Butterton, Fengjuan Xuan, Samir Gupta, Hwa-Ping Feng, John A. Wagner
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:2582-2588
Boceprevir is a potent orally administered inhibitor of hepatitis C virus and a strong, reversible inhibitor of CYP3A4, the primary metabolic pathway for many 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Thus, the aim of the
Autor:
Ellen G. J. Hulskotte, Hwa-Ping Feng, E. Hughes, Stephen P. Youngberg, Fengjuan Xuan, Joan R. Butterton, Edward O'Mara, Marga G. J. A. van Zutven, M. Treitel, John A. Wagner
Publikováno v:
Clinical Infectious Diseases. 56:718-726
BACKGROUND Boceprevir represents a new treatment option for hepatitis C (HCV)-infected patients, including those with HCV/human immunodeficiency virus coinfection; however, little is known about pharmacokinetic interactions between boceprevir and ant
Autor:
Ellen G. J. Hulskotte, Edward O'Mara, Fengjuan Xuan, Marga G. J. A. van Zutven, Samir Gupta, Joan R. Butterton, Hwa-Ping Feng, John A. Wagner
Publikováno v:
Hepatology. 56:1622-1630
The hepatitis C virus protease inhibitor boceprevir is a strong inhibitor of cytochrome P450 3A4 and 3A5 (CYP3A4/5). Cyclosporine and tacrolimus are calcineurin inhibitor immunosuppressants used to prevent organ rejection after liver transplantation;
Publikováno v:
Clinical pharmacokinetics. 54(6)
Boceprevir is a potent, orally administered ketoamide inhibitor that targets the active site of the hepatitis C virus (HCV) non-structural (NS) 3 protease. The addition of boceprevir to peginterferon plus ribavirin resulted in higher rates of sustain
Autor:
N. Reau, Hwa-Ping Feng, Janice Wahl, S.O. Klopfer, Eliav Barr, B.-Y. Nguyen, W.W. Yeh, Luzelena Caro, Peggy Hwang, Michael N. Robertson
Publikováno v:
Journal of Virus Eradication, Vol 3, Iss, Pp 34-(2017)